* ANI Pharmaceuticals Inc ANIP.OQ reported quarterly
adjusted
earnings of $1.34 per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of $1.27. The mean expectation of five analysts
for the quarter was for earnings of $1.09 per share. Wall Street
expected results to range from $1.05 to $1.15 per share.
* Revenue rose 12.5% to $148.33 million from a year ago;
analysts
expected $144.35 million.
* ANI Pharmaceuticals Inc's reported EPS for the quarter was
a
loss of $1.27.
* The company reported a quarterly loss of $24.57 million.
* ANI Pharmaceuticals Inc shares had fallen by 2.1% this
quarter and gained 5.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for ANI
Pharmaceuticals Inc is 83.00
This summary was machine generated from LSEG data November 8 at
04:20 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 1.09 1.34 Beat
Jun. 30 2024 0.95 1.02 Beat
Mar. 31 2024 1.00 1.21 Beat
Dec. 31 2023 0.86 1.00 Beat